LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE

Compare LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS (Hormone) and MEDROXYPROGESTERONE (Medroxyprogesterone) — clinical data, side effects, and patient experiences.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

· Hormone

How it works

12.1 Mechanism of Action COCs prevent pregnancy primarily by suppressing ovulation.

Approved for

1 INDICATIONS AND USAGE Introvale is indicated for use by females of reproductive potential to prevent pregnancy. Introvale is a combination of levonorgestrel

a progestin

and ethinyl estradiol

an estrogen

OralTablet

MEDROXYPROGESTERONE

Medroxyprogesterone, Provera, Depo-Provera · Hormone

How it works

Other agent

Approved for

See full prescribing information

OralTablet

Quick Comparison

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETSMEDROXYPROGESTERONE

Drug Class

Hormone

Route

Oral

Half-Life

—

FDA Approved

—

Pregnancy

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

Nausea

0.1-1%

Abdominal Pain

0.1-1%

Drug Not Working

0.1-1%

Headache

0.1-1%

MEDROXYPROGESTERONE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop if a thrombotic or thromboembolic event occurs
Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years
If feasible, stop levonorgestrel and ethinyl estradiol tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism
The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week

MEDROXYPROGESTERONE

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia
) The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders

Clinical Trial Data

No head-to-head clinical studies found for LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE: What You Should Know

Key Differences

Both LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS and MEDROXYPROGESTERONE belong to the Hormone class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS carries 4 FDA warnings. MEDROXYPROGESTERONE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Loading comparison data...

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE

Compare LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS (Hormone) and MEDROXYPROGESTERONE (Medroxyprogesterone) — clinical data, side effects, and patient experiences.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

· Hormone

How it works

12.1 Mechanism of Action COCs prevent pregnancy primarily by suppressing ovulation.

Approved for

1 INDICATIONS AND USAGE Introvale is indicated for use by females of reproductive potential to prevent pregnancy. Introvale is a combination of levonorgestrel

a progestin

and ethinyl estradiol

an estrogen

OralTablet

MEDROXYPROGESTERONE

Medroxyprogesterone, Provera, Depo-Provera · Hormone

How it works

Other agent

Approved for

See full prescribing information

OralTablet

Quick Comparison

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETSMEDROXYPROGESTERONE

Drug Class

Hormone

Route

Oral

Half-Life

—

FDA Approved

—

Pregnancy

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

Nausea

0.1-1%

Abdominal Pain

0.1-1%

Drug Not Working

0.1-1%

Headache

0.1-1%

MEDROXYPROGESTERONE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop if a thrombotic or thromboembolic event occurs
Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years
If feasible, stop levonorgestrel and ethinyl estradiol tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism
The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week

MEDROXYPROGESTERONE

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia
) The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders

Clinical Trial Data

No head-to-head clinical studies found for LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.